Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed…
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
December 05, 2025 08:00 ET | Source: Amneal Pharmaceuticals LLC Interim data show substantial improvements in “Good On” time compared…
Global sentiment analysis of 3,800 discussions from Reddit's r/Dentistry community highlights strong user recognition in software usability, workflow flexibility, and…
Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo…
SANTA CLARA, Calif., Nov. 24, 2025 /PRNewswire/ -- The Frost & Sullivan Institute is pleased to present the 2025 Visionary…
Hanover, Germany, Nov. 22, 2025 (GLOBE NEWSWIRE) -- CHC Navigation shared a significantly positive market engagement following the successful conclusion…